Why Generics

According to the U.S. Food and Drug Administration (FDA), generics are equivalent to brand drugs in terms of dosage, safety, strength, quality, the way they work and the way they’re taken.

Generics provide the same therapeutic benefits as brand drugs but at more affordable prices. Since generics use the same active ingredients and work the same way in the body as the brand, they have the same risks and benefits.

According to the U.S. Food and Drug Administration (FDA), generics are equivalent to brand drugs in terms of dosage, safety, strength, quality, the way they work and the way they’re taken.

Generics provide the same therapeutic benefits as brand drugs but at more affordable prices. Since generics use the same active ingredients and work the same way in the body as the brand, they have the same risks and benefits.

Our Generics History



1970s: By decade’s end, we produced five of the 10 most prescribed generic medicines.

1981: Mylan helps found the Generic Pharmaceutical Industry Association. The group lobbies for the Hatch-Waxman Act—a response to the high price of brand name drugs.

1989: Through congressional testimony, we help expose fraudulent practices between the Food and Drug Administration and several generics companies.

2007: We acquire Merck KGaA’s generics business, which sells products in more than 90 countries.

2012: We help drive the Generic Drug User Fee Amendments and the Food and Drug Administration Safety and Innovation Act. Both help ensure one global quality standard for all medicines entering the United States.

Therapeutic Innovation

We bring innovation to the field of generic medicine. Our research and development team include approximately 3,000 scientists and regulatory experts who innovate worldwide every day.

Today we design bioequivalent versions of brand-name medicines, many of which are difficult-to-manufacture and difficult-to-formulate.

We strive to create enhanced versions of medicines to differentiate our products from the pack. And we pursue innovations in oral solid dose medicines, transdermals, injectables, creams, ointments, antiretrovirals and nearly a dozen other critical areas.